Novel GSTP Inhibitors As Potential Oral Myelostimulants

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$250,077.00
Award Year:
2001
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
1R43CA092800-01
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SYNTRIX BIOCHIP, INC.
208 207TH AVE NE, SAMMAMISH, WA, 98053
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHN ZEBALA
() -
Business Contact:
(425) 836-9496
JZEBALA@EARTHLINK.NET
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Myelosuppression is a common complication of cancer treatment that limits the efficacy of conventional chemotherapy. It has been demonstrated that inhibiting glutathione S-transferase (GST)isozyme P1-1 in animals results in myelostimulation analogous to the action of the recombinant colony-stimulating factor G-CSF. This Phase I SBIR project will identify GSTP1-1 inhibitors that are more potent and isozyme-specific than competing inhibitors, by employing a novel structural motif in the proposed compound libraries. Screening of the libraries will be performed using an innovative and proprietary chip technology that will allow large repertoires to be synthesized and screened more easily, and with throughputs significantly better than currently available combinatorial methods. Preliminary experience with the chip technology and with model compounds suggests feasibility will be demonstrated for the chip screening technology and the proposed structural motif. Feasibility in Phase I will provide the basis for scale-up of screening and biologic testing in Phase II. Low-molecular weight GSTP1-1 inhibitors identified in Phase II that are both highly potent and isozyme-specific may lead to oral myelostimulants for treating myelosuppression during cancer therapy. PROPOSED COMMERCIAL APPLICATION: An oral myelostimulant will capture a significant portion of the market for "injection-only" factors by providing an oral substitute. The current market for recombinant factors is over $1 billion. The chip libraries will have commercial potential in the $50M research market related to drug discovery tools as "off-the-shelf" libraries. Market penetration of products will be achieved through joint ventures with established corporations.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government